| Filed On | Filing |
|---|---|
| 06 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
ATLANTA, GA – (November 5, 2026) – Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the third quarter ended September 30, 2026. |
| 27 Oct 2026 | SCHEDULE 13G/A |
| 11 Sep 2026 |
Form 4: Green Andrew M, SVP, Regulatory and Quality
Sold 11,480 shares ($287K) |
| 10 Sep 2026 | 144 |
| 04 Sep 2026 |
Form 4: Green Andrew M, SVP, Regulatory and Quality
Sold 6,510 shares ($177K) · Sold 1,493 shares ($38.8K) |
| 03 Sep 2026 | 144 |
| 02 Sep 2026 | 144 |
| 27 Aug 2026 | 144 |
| 20 Aug 2026 |
Form 4: Mackin James P, President & CEO
Sold 70,000 shares ($2.03M) |
| 19 Aug 2026 | 144 |
| 17 Aug 2026 |
Form 4: Green Andrew M, SVP, Regulatory and Quality
Sold 616 shares ($17.6K) |
| 17 Aug 2026 |
Form 4: Berry Lance A, EVP, COO, CFO & Treasurer
Sold 715 shares ($20.4K) |
| 14 Aug 2026 | 144 |
| 14 Aug 2026 | 144 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 |
Form 4: Holloway Jean F, SVP, General Counsel
Sold 977 shares ($27.8K) |
| 07 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
ATLANTA, GA – (August 6, 2026) – Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2026. |
| 06 Aug 2026 | SCHEDULE 13G/A |
Loading...